SkyQuest Technology Group recently introduced Monoclonal Antibodies Market study with in-depth overview, describing about the Product/Industry Scope and elaborates market outlook and status (2025-2032). The market Study is segmented by key regions which is accelerating the marketization. The Monoclonal Antibodies Market has witnessed Excellent growth over the past decade and is expected to maintain its upward trajectory.
Monoclonal Antibodies Market size was valued at USD 235.27 Billion in 2023 and is poised to grow from USD 262.33 Billion in 2024 to USD 626.66 Billion by 2032, growing at a CAGR of 11.5% during the forecast period (2025-2032).
An increase in requirement for biologics, especially mAbs, is mainly fuelled by the ever-rising prevalence of chronic diseases such as cancer, cardiovascular disease, and autoimmune diseases. Such trends are predicted to mark the dominating presence of the Monoclonal Antibodies Market. Increasing levels of awareness among patients and doctors are being created as monoclonal antibodies for targeted treatment start to work for significant numbers of health-care professionals. Since monoclonal antibodies can selectively interact with and neutralize disease-causing chemicals, it has emerged as one of the direct medical needs in the fight against a broad spectrum of diseases.
Get a Free Sample PDF of the Report – https://www.skyquestt.com/sample-request/monoclonal-antibodies-market
Global-leading companies in the industry have made great efforts in developing and commercializing mAb drugs. For instance, T-Cure Bioscience, Inc. collaborated with Atlas Antibodies AB in October 2021 to improve CT83 mAbs production and supply in cancer treatment applications. Of a similar sort, Ono Pharmaceutical Co., Ltd. and Neurimmune AG agreed in January 2022 to collaborate for developing mAb drugs targeting novel therapeutic targets of neurodegenerative diseases. These new and innovative partnerships are most expected to unlock opportunities for growth of the mAbs sector with regard to improved treatment options and betterment of patient care for most chronic conditions.
Detailed Segmentation and Classification of the report (Market Size and Forecast – 2032, Y-o-Y growth rate, and CAGR):
The Monoclonal Antibodies Market can be segmented based on several factors, including product type, application, end-user, and distribution channel.
Source type
Murine, Chimeric, Humanized, Human
Production Type
In Vivo, In Vitro
Application
Oncology, Autoimmune Diseases, Infectious Diseases, Neurological Diseases, Others
End-use
Hospitals, Specialty Centers, Others
Monoclonal Antibodies Market – Regional Analysis:
– Monoclonal Antibodies North America Market includes (Canada, Mexico, USA)
– Monoclonal Antibodies Europe Market includes (Germany, France, Great Britain, Italy, Spain, Russia)
– Monoclonal Antibodies Asia-Pacific Market includes (China, Japan, India, South Korea, Australia)
– Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa)
– Monoclonal Antibodies South America Market includes (Brazil, Argentina)
– Monoclonal Antibodies Oceania Market (Australia & New Zealand)
Top Market Players in Monoclonal Antibodies Market are:
Novartis AG (Switzerland)
Pfizer Inc. (US)
GlaxoSmithKline plc (UK)
Amgen Inc. (US)
Merck & Co., Inc. (US)
Daiichi Sankyo Company, Limited (Japan)
Abbott Laboratories (US)
AstraZeneca plc (UK)
Eli Lilly and Company (US)
Johnson & Johnson Services, Inc. (US)
Bayer AG (Germany)
Bristol Myers Squibb (US)
F. Hoffmann-La Roche Ltd. (Switzerland)
Viatris Inc. (US)
Biogen Inc. (US)
Thermo Fisher Scientific, Inc. (US)
Novo Nordisk A/S (Denmark)
Sanofi S.A. (France)
Merck KGaA (Germany)
Genmab A/S (Denmark)
Regeneron Pharmaceuticals, Inc. (US)
Incyte Corporation (US)
Recent Developments:
Roche, the leading pharmaceutical company from Switzerland, announced in March 2024 that the company will launch the monoclonal antibodies for the two serious eye conditions in the Indian market. The newly launched Vabysmo is aimed at treating diabetic macular edema (DME) and neovascular or “wet” age-related macular degeneration (nAMD).
The newly formed Calluna Pharma, which resulted from the merger of Oxitope Pharma and Arxx Therapeutics, revealed in January 2024 that it has received USD 81 million in cash through a Series A funding round. With a pipeline of four highly promising prospects in monoclonal antibodies, the company will continue to use these funds.
KBI Biopharma has just launched a new platform in December 2023 that speeds the development and manufacturing of monoclonal antibodies. The newest offering, SUREmAb, is built on top of KBI’s SUREtechnology Platform.
Also Read –
https://pando.life/article/369734
http://prsync.com/skyquest-technology-consulting-pvt-ltd/the-future-of-construction-growth-trends-in-construction-chemicals–ready-mix-concrete-markets-4692286/
Forward-Looking Insights
The Monoclonal Antibodies Market is set to experience sustained growth, fueled by technological advancements, broader market access, and rising industry demand. With the industry addressing emerging challenges and capitalizing on new opportunities, it is expected to drive innovation and play a pivotal role in advancing health and economic progress.
About Company:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact Details:
SkyQuest Technology Group
USA (+1) 351-333-4748
Email: [email protected]
